Provider Briefing: Lokelma Availability in 2026

As a prescriber of Lokelma (Sodium Zirconium Cyclosilicate), you've likely fielded calls from patients who can't fill their prescriptions. The question comes up repeatedly in nephrology and cardiology practices: Is Lokelma in shortage? Why can't my patients get it?

This briefing provides a comprehensive, evidence-based overview of Lokelma's current availability landscape, practical prescribing considerations, and resources you can use to help your patients maintain access to this important potassium binder.

Current Shortage Status

As of March 2026, Lokelma is not listed on the FDA Drug Shortage Database or the ASHP Drug Shortages List. AstraZeneca, the sole manufacturer, has not reported any supply disruptions.

However, the distinction between a formal shortage and real-world access barriers is clinically relevant. Patients routinely encounter the following obstacles:

• Pharmacy stocking gaps: Most retail pharmacies do not routinely stock Lokelma due to its specialty classification and relatively narrow patient population
• Distribution delays: Even when nationally available, wholesale distribution to smaller or rural pharmacies can be inconsistent
• Insurance friction: Prior authorization requirements and step therapy protocols create delays that can leave patients without coverage for days to weeks

These are access issues, not manufacturing shortages — but the clinical impact on patients who need consistent potassium management is the same.

Timeline and Context

Understanding Lokelma's market position helps frame current availability:

• May 2018: FDA approval of Lokelma for treatment of hyperkalemia in adults
• 2020: Supplemental approval for dosing in hemodialysis patients (administer on non-dialysis days only)
• 2018–2026: No generic competition; AstraZeneca remains the sole manufacturer
• 2024–2025: Increased prescribing volume as clinical guidelines increasingly favor newer potassium binders (Lokelma, Veltassa) over Kayexalate for chronic hyperkalemia management
• 2026: Growing awareness but persistent access barriers related to specialty drug distribution and payer coverage

The drug shortage landscape in the United States has been significant in recent years — ASHP reported 323 active shortages at the peak in Q1 2024. While Lokelma has not been among them, the broader supply chain stress has heightened both provider and patient sensitivity to availability concerns.

Prescribing Implications

When prescribing Lokelma in the current environment, several practical considerations are worth noting:

Anticipate Pharmacy Lead Time

Because most retail pharmacies don't stock Lokelma, advise patients that their pharmacy may need 1-3 business days to order it. For new starts, consider:

• Writing the prescription several days before the patient runs out of any bridge therapy
• Directing patients to specialty pharmacies or pharmacies known to stock potassium binders
• Using Medfinder for Providers to identify pharmacies with current stock in your area

Insurance Navigation

Lokelma is typically classified as a Tier 4 (specialty) drug on most formularies. Common payer requirements include:

• Prior authorization: Most commercial plans and many Medicare Part D plans require PA for Lokelma
• Step therapy: Some plans require documentation that the patient has tried and failed Kayexalate (SPS) before covering Lokelma
• Quantity limits: Plans may impose monthly quantity limits aligned with standard dosing

When submitting prior authorizations, documenting the clinical rationale thoroughly — particularly noting GI intolerability or safety concerns with Kayexalate, the need to maintain RAAS inhibitor therapy, or CKD/heart failure comorbidities — improves approval rates.

Dosing Reminders

• Correction phase: 10g TID for up to 48 hours
• Maintenance: 5g once daily; titrate based on serum potassium (range: 5g QOD to 10g daily)
• Hemodialysis patients: 5g once daily on non-dialysis days only; may increase to 15g daily on non-dialysis days
• Drug interactions: Other oral medications should be administered at least 2 hours before or after Lokelma due to transient gastric pH elevation
• Sodium content: Each 5g dose contains approximately 400mg sodium — relevant for patients on sodium-restricted diets or with decompensated heart failure

Availability Picture: Where Patients Can Find Lokelma

Help your patients navigate the availability landscape with these resources:

Medfinder for Providers

Medfinder allows both providers and patients to search for pharmacies with Lokelma in stock in real time. This eliminates the inefficient phone-call approach and can be integrated into your patient discharge or prescription workflow.

Specialty Pharmacies

Specialty pharmacies that focus on nephrology or cardiology patients are the most reliable sources for Lokelma. If your practice doesn't already have relationships with specialty pharmacies, consider establishing referral pathways for patients requiring specialty medications.

Mail-Order Options

Many insurance plans include mail-order pharmacy benefits that cover Lokelma with home delivery. For patients in rural areas or those who face consistent local pharmacy access issues, mail-order can be the most reliable option for ongoing maintenance therapy.

Cost and Access Considerations

Understanding the cost landscape helps you counsel patients and navigate insurance barriers:

• Cash price: $843–$1,150/month for maintenance dosing (5g daily)
• AstraZeneca Co-pay Savings Card: Commercially insured patients may pay as little as $0/month (not available for government-insured patients)
• AZ&Me Patient Assistance Program: Free medication for qualifying uninsured/underinsured patients meeting income criteria
• Third-party assistance: Organizations like Prescription Hope ($70/month) and The Rx Advocates ($80/month) offer additional pathways
• Kayexalate (generic SPS): $20–$60/month — relevant as a cost-driven alternative or step therapy requirement

AstraZeneca's My Access 360 program (myaccess360.com) provides comprehensive support including benefits verification, prior authorization assistance, copay support, and patient assistance enrollment. This is the single most useful resource to share with your office staff and patients.

Tools and Resources for Your Practice

Here is a summary of actionable resources:

• Medfinder for Providers — Real-time pharmacy stock lookup for Lokelma and other specialty medications
• My Access 360 (myaccess360.com) — AstraZeneca's patient support hub for insurance navigation, copay cards, and patient assistance
• Lokelma HCP Website — Prescribing information, dosing guidelines, formulary finder, and clinical resources
• ASHP Drug Shortages (ashp.org/drug-shortages) — Monitor for any future shortage listings

Alternative Agents: When to Consider Switching

If a patient cannot access Lokelma, the primary alternatives are:

• Veltassa (Patiromer): Comparable newer-generation potassium binder. Slower onset (4-7 hours vs. 1 hour for Lokelma). Requires 3-hour separation from other oral medications. May be covered differently by the patient's insurer.
• Kayexalate (SPS): Oldest available option. Significantly cheaper but carries higher GI side effect burden and rare risk of intestinal necrosis, particularly with concomitant sorbitol. May be appropriate as a short-term bridge.
• Dose adjustment of causative agents: For patients whose hyperkalemia is driven by RAAS inhibitors, consider whether dose reduction is clinically acceptable — though the goal of potassium binder therapy is often to maintain optimal RAAS inhibition.

For a patient-facing comparison of these options, you may find it helpful to share our article on alternatives to Lokelma with your patients.

Looking Ahead

Several developments may improve Lokelma access in the coming years:

• Potential generic entry: While no generic Sodium Zirconium Cyclosilicate is currently approved, eventual patent expiration will open the market to competition
• Expanding formulary coverage: As clinical evidence continues to support newer potassium binders over Kayexalate for chronic management, more payers are expected to improve coverage
• Specialty pharmacy growth: The continued expansion of specialty pharmacy networks improves the distribution pipeline for niche medications
• Digital availability tools: Platforms like Medfinder are closing the information gap between manufacturers, pharmacies, and patients

Final Thoughts

Lokelma is not in formal shortage, but real-world access challenges persist. As prescribers, the most impactful steps you can take are: (1) directing patients to reliable pharmacy sources, (2) proactively navigating insurance barriers, and (3) staying informed about the evolving availability landscape.

Hyperkalemia management is foundational to safe RAAS inhibitor therapy in CKD and heart failure. Ensuring your patients can consistently access their prescribed potassium binder is as important as the prescribing decision itself.

For more provider-focused resources, visit medfinder.com/providers.